Ziv-Aflibercept Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV)
Available Strengths: 25mg/ml
Reference Brands: Zaltrap® (US & EU)
Category:
Oncology Cancer Care
Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis. It targets vascular endothelial growth factor (VEGF), preventing tumor blood vessel growth. Available as an intravenous (IV) injection with a strength of 25 mg/mL, it is used in combination with chemotherapy for mCRC treatment. Ziv-aflibercept is available in both the US and EU, helping improve outcomes for patients with advanced colorectal cancer.
Ziv-aflibercept is available in Intravenous (IV)
and strengths such as 25mg/ml.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ziv-aflibercept is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ziv-aflibercept can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis – the process of new blood vessel formation that tumors need to grow. It works by targeting and binding to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), preventing their interaction with receptors on endothelial cells, thus blocking tumor blood vessel formation. Ziv-aflibercept is typically administered in combination with chemotherapy and is available in the US and EU in an intravenous (IV) formulation
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing